Clinical trial
BMS-214662 in Treating Patients With Advanced Solid Tumors
NCT00006242 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00006242 |
|---|---|
| Title | BMS-214662 in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase I Trial of Farnesyltransferase Inhibitor BMS-214662 (NSC 710086) Escalating to a 24 Hour Continuous Intravenous Infusion in Patients With Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | BMS-214662, laboratory biomarker analysis, pharmacological study |
| Enrollment | 40 |
| Start date | Jul 1, 2000 |
| Primary completion | Sep 1, 2005 |
| First posted | May 22, 2003 |
| Last update posted | Feb 1, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: